VCRE (Vicore Pharma Holding AB) 5-Year EBITDA Growth Rate: 13.60% (As of Mar. 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $13.65
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB 5-Year EBITDA Growth Rate?

Vicore Pharma Holding AB VCRE -5.82% 13 5-Year EBITDA Growth Rate is 13.60% as of Mar. 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

Vicore Pharma Holding AB's EBITDA per Share for the three months ended in Mar. 2026 was $-0.04.

During the past 3 years, the average EBITDA Per Share Growth Rate was 19.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 13.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vicore Pharma Holding AB was 33.20% per year. The lowest was -65.90% per year. And the median was -23.10% per year.

Vicore Pharma Holding AB  (NAS:VCRE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Vicore Pharma Holding AB 5-Year EBITDA Growth Rate Related Terms

VCRE vs : 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 13.60% mean?
Vicore Pharma Holding AB (VCRE) has a 5-Year EBITDA Growth Rate of 13.60% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate too high?
Vicore Pharma Holding AB's current 5-Year EBITDA Growth Rate is 13.60%. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate compare to ?
Vicore Pharma Holding AB's 5-Year EBITDA Growth Rate of 13.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current 5-Year EBITDA Growth Rate is 13.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current 5-Year EBITDA Growth Rate of 13.60%. The current 5-Year EBITDA Growth Rate is 13.60%. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current 5-Year EBITDA Growth Rate is 13.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.65
Price